paroxetine has been researched along with sumatriptan in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (25.00) | 18.2507 |
| 2000's | 10 (50.00) | 29.6817 |
| 2010's | 5 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Ahman, M; Holmén, AG; Wan, H | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Cleves, AE; Jain, AN; Kirshner, D; Langham, JJ; Spitzer, R | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Meyer, C | 1 |
| Blier, P; Piñeyro, G | 1 |
| Campling, GM; Clifford, EM; Cowen, PJ; Hockney, RA; Sheehan, BD; Wing, YK | 1 |
| Abraham, JT; Brown, R; Meltzer, HY | 1 |
| Davidson, C; Stamford, JA | 2 |
| Koran, LM; Pallanti, S; Quercioli, L | 1 |
| Hendrix, Y; van Zagten, MS | 1 |
1 review(s) available for paroxetine and sumatriptan
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 trial(s) available for paroxetine and sumatriptan
| Article | Year |
|---|---|
Paroxetine treatment and the prolactin response to sumatriptan.
Topics: Adult; Blood Pressure; Body Temperature; Drug Combinations; Humans; Male; Middle Aged; Paroxetine; Prolactin; Selective Serotonin Reuptake Inhibitors; Serotonin Receptor Agonists; Sumatriptan | 1996 |
Sumatriptan, 5-HT(1D) receptors and obsessive-compulsive disorder.
Topics: Adolescent; Adult; Double-Blind Method; Female; Humans; Male; Middle Aged; Obsessive-Compulsive Disorder; Paroxetine; Psychiatric Status Rating Scales; Receptor, Serotonin, 5-HT1D; Receptors, Serotonin; Selective Serotonin Reuptake Inhibitors; Serotonin Receptor Agonists; Sumatriptan | 2001 |
17 other study(ies) available for paroxetine and sumatriptan
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution | 2004 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
Topics: Brain; Central Nervous System; Chromatography, Liquid; Emulsions; Mass Spectrometry | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physical binding pocket induction for affinity prediction.
Topics: Binding Sites; Ligands; Models, Molecular; Neural Networks, Computer; Peptide Fragments; Protein Binding; Receptor, Serotonin, 5-HT1A | 2009 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
New drugs. In the realm of the brain.
Topics: Central Nervous System Agents; Depression; Humans; Hypnotics and Sedatives; Migraine Disorders; Paroxetine; Pyridines; Sleep Initiation and Maintenance Disorders; Sumatriptan; Zolpidem | 1993 |
Regulation of 5-hydroxytryptamine release from rat midbrain raphe nuclei by 5-hydroxytryptamine1D receptors: effect of tetrodotoxin, G protein inactivation and long-term antidepressant administration.
Topics: Animals; Antidepressive Agents; GTP-Binding Proteins; Male; Oxazoles; Paroxetine; Potassium; Raphe Nuclei; Rats; Rats, Sprague-Dawley; Receptors, Serotonin; Serotonin; Sumatriptan; Tetrodotoxin | 1996 |
Clozapine treatment of persistent paroxysmal dyskinesia associated with concomitant paroxetine and sumatriptan use.
Topics: Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Bipolar Disorder; Clozapine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Neurologic Examination; Paroxetine; Serotonin Receptor Agonists; Sumatriptan | 1997 |
Chronic paroxetine desensitises 5-HT1D but not 5-HT1B autoreceptors in rat lateral geniculate nucleus.
Topics: Animals; Autoreceptors; Geniculate Bodies; Male; Paroxetine; Pyridines; Pyrroles; Rats; Rats, Wistar; Receptors, Serotonin; Selective Serotonin Reuptake Inhibitors; Serotonin Receptor Agonists; Sumatriptan; Time Factors | 1997 |
Effect of chronic paroxetine treatment on 5-HT1B and 5-HT1D autoreceptors in rat dorsal raphe nucleus.
Topics: Animals; Electric Stimulation; Male; Paroxetine; Piperazines; Pyridines; Pyrroles; Raphe Nuclei; Rats; Rats, Wistar; Receptor, Serotonin, 5-HT1B; Receptor, Serotonin, 5-HT1D; Receptors, Serotonin; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Antagonists; Serotonin Receptor Agonists; Sumatriptan | 2000 |
[Serotonin syndrome as a result of concomitant use of paroxetine and sumatriptan].
Topics: Aged; Brain Stem; Drug Synergism; Female; Humans; Paroxetine; Receptors, Serotonin; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Receptor Agonists; Sumatriptan; Syndrome; Treatment Outcome | 2005 |